-
公开(公告)号：US20180258430A1
公开(公告)日：2018-09-13
申请号：US15990330
申请日：2018-05-25
Applicant: Arrowhead Pharmaceuticals, Inc.
Inventor： Christine I. Wooddell , David L. Lewis , Darren H. Wakefield , Lauren Almeida , Steven B. Kanner
IPC: C12N15/113
CPC classification number: C12N15/113 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/323 , C12N2310/3515 , C12N2310/3533 , C12N2310/3521
Abstract: The invention relates to a RNA interference triggers for inhibiting the expression of an AAT gene through the mechanism of RNA interference. The invention also relates to a pharmaceutical composition comprising the AAT RNAi trigger together with an excipient capable of improving delivery of the RNAi trigger to a liver cell in vivo. Delivery of the AAT RNAi trigger to liver cells in vivo provides for inhibition of AAT gene expression and treatment of alpha 1-antitrypsin deficiency and associated diseases.
-
公开(公告)号：US20210180066A1
公开(公告)日：2021-06-17
申请号：US17179605
申请日：2021-02-19
Applicant: Arrowhead Pharmaceuticals, Inc.
Inventor： So Wong , David L. Lewis , David B. Rozema , Darren H. Wakefield , Steven B. Kanner , Weijun Cheng , Lauren J. Almeida , Andrei V. Blokhin , Jeffrey C. Carlson , Anthony L. Nicholas , Aaron Almeida , Jonathan D. Benson , Justin Woods
IPC: C12N15/113 , A61K31/713 , A61K45/06 , A61K47/60 , A61K47/64
Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2α (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2α RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2α RNAi triggers to tumor cells in vivo provides for inhibition of Hif2α gene expression and treatment of cancer.
-
公开(公告)号：US11840688B2
公开(公告)日：2023-12-12
申请号：US17179605
申请日：2021-02-19
Applicant: Arrowhead Pharmaceuticals, Inc.
Inventor： So Wong , David L. Lewis , David B. Rozema , Darren H. Wakefield , Steven B. Kanner , Weijun Cheng , Lauren J. Almeida , Andrei V. Blokhin , Jeffrey C. Carlson , Anthony L. Nicholas , Aaron Almeida , Jonathan D. Benson , Justin Woods
IPC: C12N15/113 , A61K31/713 , A61K45/06 , A61K47/60 , A61K47/64
CPC classification number: C12N15/113 , A61K31/713 , A61K45/06 , A61K47/60 , A61K47/64 , C12N2310/14 , C12N2310/315 , C12N2310/343 , C12N2310/346 , C12N2310/351 , C12N2320/31 , C12N2320/32 , C12N2310/322 , C12N2310/3533 , C12N2310/321 , C12N2310/3521
Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2α (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2α RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2α RNAi triggers to tumor cells in vivo provides for inhibition of Hif2α gene expression and treatment of cancer.
-
公开(公告)号：US20230002768A1
公开(公告)日：2023-01-05
申请号：US17834988
申请日：2022-06-08
Applicant: Arrowhead Pharmaceuticals, Inc.
Inventor： Christine I. Wooddell , David L. Lewis , Darren H. Wakefield , Lauren Almeida , Steven B. Kanner
IPC: C12N15/113
Abstract: The invention relates to a RNA interference triggers for inhibiting the expression of an AAT gene through the mechanism of RNA interference. The invention also relates to a pharmaceutical composition comprising the AAT RNAi trigger together with an excipient capable of improving delivery of the RNAi trigger to a liver cell in vivo. Delivery of the AAT RNAi trigger to liver cells in vivo provides for inhibition of AAT gene expression and treatment of alpha 1-antitrypsin deficiency and associated diseases.
-
公开(公告)号：US20180023086A1
公开(公告)日：2018-01-25
申请号：US15715765
申请日：2017-09-26
Applicant: Arrowhead Pharmaceuticals, Inc.
Inventor： Steven B. Kanner , David L. Lewis , Darren H. Wakefield , Lauren J. Almeida
IPC: C12N15/113 , A61K47/42 , A61K31/713 , A61K9/00
CPC classification number: C12N15/1137 , A61K9/0019 , A61K31/713 , A61K45/06 , A61K47/42 , A61K47/554 , C12N15/113 , C12N2310/14 , C12N2310/315 , C12N2310/322 , C12N2310/351 , C12N2310/3515 , C12N2320/30
Abstract: RNA interference (RNAi) triggers for inhibiting the expression of Factor XII (F12) gene through the mechanism of RNA interference are described. Pharmaceutical compositions comprising one or more F12 RNAi triggers together with one or more excipients capable of delivering the RNAi trigger(s) to a liver cell in vivo are also described. Delivery of the F12 RNAi trigger(s) to liver cells in vivo provides for inhibition of F12 gene expression and treatment of angioedema, including hereditary angioedema (HAE) and venous thromboembolism (VTE), and diseases associated with angioedema.
-
公开(公告)号：US12188017B2
公开(公告)日：2025-01-07
申请号：US17834988
申请日：2022-06-08
Applicant: Arrowhead Pharmaceuticals, Inc.
Inventor： Christine I. Wooddell , David L. Lewis , Darren H. Wakefield , Lauren Almeida , Steven B. Kanner
IPC: C12N15/113
Abstract: The invention relates to a RNA interference triggers for inhibiting the expression of an AAT gene through the mechanism of RNA interference. The invention also relates to a pharmaceutical composition comprising the AAT RNAi trigger together with an excipient capable of improving delivery of the RNAi trigger to a liver cell in vivo. Delivery of the AAT RNAi trigger to liver cells in vivo provides for inhibition of AAT gene expression and treatment of alpha 1-antitrypsin deficiency and associated diseases.
-
公开(公告)号：US10927373B2
公开(公告)日：2021-02-23
申请号：US15954316
申请日：2018-04-16
Applicant: Arrowhead Pharmaceuticals, Inc.
Inventor： So Wong , David L. Lewis , David B. Rozema , Darren H. Wakefield , Steven B. Kanner , Weijun Cheng , Lauren J. Almeida , Andrei V. Blokhin , Jeffrey C. Carlson , Anthony L. Nicholas , Aaron Almeida , Jonathan D. Benson , Justin Woods
IPC: C12N15/113 , A61K31/713 , A61K45/06 , A61K47/60 , A61K47/64
Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2α (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2α RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2α RNAi triggers to tumor cells in vivo provides for inhibition of Hif2α gene expression and treatment of cancer.
-
公开(公告)号：US20190359984A1
公开(公告)日：2019-11-28
申请号：US16429501
申请日：2019-06-03
Applicant: Arrowhead Pharmaceuticals, Inc.
Inventor： Steven B. Kanner , David L. Lewis , Darren H. Wakefield , Lauren J. Almeida
IPC: C12N15/113 , A61K47/42 , A61K31/713 , A61K45/06 , A61K47/54
Abstract: RNA interference (RNAi) triggers for inhibiting the expression of Factor XII (F12) gene through the mechanism of RNA interference are described. Pharmaceutical compositions comprising one or more F12 RNAi triggers together with one or more excipients capable of delivering the RNAi trigger(s) to a liver cell in vivo are also described. Delivery of the F12 RNAi trigger(s) to liver cells in vivo provides for inhibition of F12 gene expression and treatment of angioedema, including hereditary angioedema (HAE) and venous thromboembolism (VTE), and diseases associated with angioedema.
-
公开(公告)号：US10308941B2
公开(公告)日：2019-06-04
申请号：US15715765
申请日：2017-09-26
Applicant: Arrowhead Pharmaceuticals, Inc.
Inventor： Steven B. Kanner , David L. Lewis , Darren H. Wakefield , Lauren J. Almeida
IPC: C12N15/113 , A61K31/713 , A61K47/42 , A61K47/54 , A61K45/06 , A61K9/00
Abstract: RNA interference (RNAi) triggers for inhibiting the expression of Factor XII (F12) gene through the mechanism of RNA interference are described. Pharmaceutical compositions comprising one or more F12 RNAi triggers together with one or more excipients capable of delivering the RNAi trigger(s) to a liver cell in vivo are also described. Delivery of the F12 RNAi trigger(s) to liver cells in vivo provides for inhibition of F12 gene expression and treatment of angioedema, including hereditary angioedema (HAE) and venous thromboembolism (VTE), and diseases associated with angioedema.
-
公开(公告)号：US10858658B2
公开(公告)日：2020-12-08
申请号：US16429501
申请日：2019-06-03
Applicant: Arrowhead Pharmaceuticals, Inc.
Inventor： Steven B. Kanner , David L. Lewis , Darren H. Wakefield , Lauren J. Almeida
IPC: C12N15/113 , A61K31/713 , A61K47/42 , A61K47/54 , A61K45/06 , A61K9/00
Abstract: RNA interference (RNAi) triggers for inhibiting the expression of Factor XII (F12) gene through the mechanism of RNA interference are described. Pharmaceutical compositions comprising one or more F12 RNAi triggers together with one or more excipients capable of delivering the RNAi trigger(s) to a liver cell in vivo are also described. Delivery of the F12 RNAi trigger(s) to liver cells in vivo provides for inhibition of F12 gene expression and treatment of angioedema, including hereditary angioedema (HAE) and venous thromboembolism (VTE), and diseases associated with angioedema.
